RBX2660
Phase 3Biologic
FerringRBX2660 is one of 36 biologic programs targeting Clostridium Difficile Infection. It is currently in Phase 3.
3
Indications
6
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
53 competitors in Clostridium Difficile Infection
#DrugCompanyPhaseTrials
1Dificlir
Merck & Co.Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
ZINPLAVA
Merck & Co.Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Alinia
RRomark Laboratories L.C.
Phase 3
Imodium
KKenvue Brands
Phase 3
Flagyl
DDePuy Orthopaedics
Phase 2
RBX2660
FerringPhase 3
Glutamine
SanofiPhase 2
MK-3415A
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clostridium Difficile Infection4 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RBX2660. EMBL-EBI & Wellcome Sanger Institute.
- [4]